Xu, Wen
The University of Queensland · Princess Alexandra Hospital
2 papers on CoChatORCID 0000-0002-9109-2363
Most cited papers
- Verified
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., et al. (2020) · The Lancet Oncology
Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling
Cited by 78
- Verified
620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion
Shenderov, E., Mallesara, G. H. G., Wysocki, P. J., Xu, W., Ramlau, R., Weickhardt, A. J., Zolnierek, J., Spira, A., Joshua, A. M., Powderly, J., et al. (2021) · Annals of Oncology
Monoclonal and Polyclonal Antibodies ResearchProtein Degradation and Inhibitors
Cited by 28
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free